Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H21Cl2N3O5 |
| Molecular Weight | 478.325 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(COC(=O)N2CCN(CCC(=O)C3=CC4=C(NC(=O)O4)C=C3)CC2)=CC(Cl)=C1
InChI
InChIKey=JMSUDQYHPSNBSN-UHFFFAOYSA-N
InChI=1S/C22H21Cl2N3O5/c23-16-9-14(10-17(24)12-16)13-31-22(30)27-7-5-26(6-8-27)4-3-19(28)15-1-2-18-20(11-15)32-21(29)25-18/h1-2,9-12H,3-8,13H2,(H,25,29)
| Molecular Formula | C22H21Cl2N3O5 |
| Molecular Weight | 478.325 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20392816 | https://www.ncbi.nlm.nih.gov/pubmed/24062988Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23300119
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20392816 | https://www.ncbi.nlm.nih.gov/pubmed/24062988
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23300119
PF-8380 is a potent autotaxin inhibitor with an IC(50) of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood. Inhibition of ATX by PF-8380 led to decreased invasion and enhanced radiosensitization of GBM cells.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. | 2010 Jul |
|
| Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines. | 2013 |
|
| PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability. | 2013 Feb |
Patents
Sample Use Guides
Rats: Oral administration of 30 mg/kg PF-8380 reduces inflammatory hyperalgesia in a rat air pouch model, exhibiting >95% reduction of LPA levels in both plasma and inflammatory site tissue within 3 hours
Route of Administration:
Oral
Pre-treatment of GL261 and U87-MG cells with 1 uM PF-8380 followed by 4 Gy irradiation resulted in decreased clonogenic survival, decreased migration (33% in GL261; P = 0.002 and 17.9% in U87-MG; P = 0.012), decreased invasion (35.6% in GL261; P = 0.0037 and 31.8% in U87-MG; P = 0.002), and attenuated radiation-induced Akt phosphorylation.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:49:54 GMT 2023
by
admin
on
Sat Dec 16 11:49:54 GMT 2023
|
| Record UNII |
T582DIM5A4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
25265312
Created by
admin on Sat Dec 16 11:49:54 GMT 2023 , Edited by admin on Sat Dec 16 11:49:54 GMT 2023
|
PRIMARY | |||
|
1144035-53-9
Created by
admin on Sat Dec 16 11:49:54 GMT 2023 , Edited by admin on Sat Dec 16 11:49:54 GMT 2023
|
PRIMARY | |||
|
DTXSID50649524
Created by
admin on Sat Dec 16 11:49:54 GMT 2023 , Edited by admin on Sat Dec 16 11:49:54 GMT 2023
|
PRIMARY | |||
|
T582DIM5A4
Created by
admin on Sat Dec 16 11:49:54 GMT 2023 , Edited by admin on Sat Dec 16 11:49:54 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
